Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights
Provided By GlobeNewswire
Last update: Nov 5, 2025
FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application
Read more at globenewswire.com
